Renaissance Technologies (RenTech)'s PYXS Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 772,232 shares of Pyxis Oncology, Inc. (PYXS) worth $2.32 M, representing 0.00% of the portfolio. First purchased in 2022-Q2, this medium-term investment has been held for 17 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in PYXS, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2025, adding 288,782 shares. Largest reduction occurred in Q1 2024, reducing 216,150 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Pyxis Oncology (PYXS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Pyxis Oncology (PYXS) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | -116,448 | Reduce 13.10% | 772,232 | $3.01 |
| Q1 2026 | +160,300 | Add 22.01% | 888,680 | $1.46 |
| Q4 2025 | +152,044 | Add 26.38% | 728,380 | $1.15 |
| Q3 2025 | +158,514 | Add 37.94% | 576,336 | $2.22 |
| Q2 2025 | -164,314 | Reduce 28.23% | 417,822 | $1.10 |
| Q1 2025 | +288,782 | Add 98.44% | 582,136 | $0.98 |
| Q4 2024 | +133,018 | Add 82.96% | 293,354 | $1.56 |
| Q3 2024 | +63,400 | Add 65.40% | 160,336 | $3.67 |
| Q2 2024 | -51,064 | Reduce 34.50% | 96,936 | $3.31 |
| Q1 2024 | -216,150 | Reduce 59.36% | 148,000 | $4.26 |
| Q4 2023 | +147,899 | Add 68.39% | 364,150 | $1.80 |
| Q3 2023 | -36,978 | Reduce 14.60% | 216,251 | $1.99 |
| Q2 2023 | +159,029 | Add 168.82% | 253,229 | $0.00 |
| Q1 2023 | +10,600 | Add 12.68% | 94,200 | $0.00 |
| Q4 2022 | -45,202 | Reduce 35.09% | 83,600 | $0.00 |
| Q3 2022 | +53,431 | Add 70.89% | 128,802 | $1.97 |
| Q2 2022 | +75,371 | New Buy | 75,371 | $2.37 |
Renaissance Technologies (RenTech)'s Pyxis Oncology Investment FAQs
Renaissance Technologies (RenTech) first purchased Pyxis Oncology, Inc. (PYXS) in Q2 2022, acquiring 75,371 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Pyxis Oncology, Inc. (PYXS) for 17 quarters since Q2 2022.
Renaissance Technologies (RenTech)'s largest addition to Pyxis Oncology, Inc. (PYXS) was in Q1 2025, adding 582,136 shares worth $570,435.
According to the latest 13F filing for Q2 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 772,232 shares of Pyxis Oncology, Inc. (PYXS), valued at approximately $2.32 M.
As of the Q2 2026 filing, Pyxis Oncology, Inc. (PYXS) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Pyxis Oncology, Inc. (PYXS) was 888,680 shares, as reported at the end of Q1 2026.